Drugs / prourokinase

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07550296 May 2026 → Dec 2027 expected ischemic stroke General Hospital of Shenyang Military Region Recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT06841965 Mar 2025 → Jun 2027 expected ischemic stroke Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
Phase 3 NCT06841978 Mar 2025 → Jun 2027 expected ischemic stroke Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
Phase 3 NCT06749834 Jan 2025 → Dec 2026 expected ischemic stroke Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 42 trials
Phase 4 NCT06115070 Mar 2025 → Dec 2027 expected ischemic stroke, thrombotic disease Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
Phase 4 NCT02131220 Nov 2015 → Aug 2017 myocardial infarction Fudan University Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT01642667 Comparator Nov 2008 → Nov 2009 ST-elevation myocardial infarction Suzhou Landing Pharmaceuticals Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as prourokinase “intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).” NCT06841965
6

“intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes)” NCT06749834

“intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes)” NCT06115070

“intravenous prourokinase (rhPro-UK)” NCT06841978

NCT07550296

NCT02131220

NCT01642667

Known as rhPro-UK “intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).” NCT06841965
3

“intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes)” NCT06749834

“intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes)” NCT06115070

“intravenous prourokinase (rhPro-UK)” NCT06841978

Modality Protein / enzyme biologic “Recombinant HUman Prourokinase” NCT02131220
Route Other “20mg intracoronary bolus infusion using selective catheter during PCI” NCT02131220